Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.5190
+0.0037 (0.72%)
At close: Jun 11, 2025, 4:00 PM
0.5090
-0.0100 (-1.93%)
Pre-market: Jun 12, 2025, 7:51 AM EDT
Sangamo Therapeutics Revenue
Sangamo Therapeutics had revenue of $6.44M in the quarter ending March 31, 2025, with 1,238.25% growth. This brings the company's revenue in the last twelve months to $63.76M, up 239.92% year-over-year. In the year 2024, Sangamo Therapeutics had annual revenue of $57.80M, down -67.20%.
Revenue (ttm)
$63.76M
Revenue Growth
+239.92%
P/S Ratio
1.72
Revenue / Employee
$348,393
Employees
183
Market Cap
123.31M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.80M | -118.43M | -67.20% |
Dec 31, 2023 | 176.23M | 64.93M | 58.34% |
Dec 31, 2022 | 111.30M | 598.00K | 0.54% |
Dec 31, 2021 | 110.70M | -7.49M | -6.34% |
Dec 31, 2020 | 118.19M | 15.76M | 15.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SGMO News
- 4 weeks ago - Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Business Wire
- 4 weeks ago - Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day - Business Wire
- 5 weeks ago - Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Business Wire
- 5 weeks ago - Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease - Business Wire
- 6 weeks ago - Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Business Wire
- 2 months ago - Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal - Seeking Alpha